MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.780
0.000
0.00%
After Hours: 2.780 0 0.00% 16:00 10/23 EDT
OPEN
2.740
PREV CLOSE
2.780
HIGH
2.900
LOW
2.725
VOLUME
240.06K
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
1.250
MARKET CAP
146.37M
P/E (TTM)
-4.6488
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AVXL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AVXL News

  • All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
  • Zacks.7h ago
  • Edited Transcript of AVXL earnings conference call or presentation 7-Aug-19 8:30pm GMT
  • Thomson Reuters StreetEvents.10/11 03:07
  • Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimers Disease
  • GlobeNewswire.10/09 12:00
  • Anavex Life Sciences (AVXL) Presents At 6th Annual European Rett Syndrome Conference - Slideshow September 2019 (Finland)
  • Seeking Alpha - Article.10/03 16:32

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Name
Price
%Change

About AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
More

Webull offers Anavex Life Sciences Corp (AVXL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.